Lilly Points To Six-Month Growth Instead Of Pandemic Impacted Q2

30 Jul 2020

Lilly argues the overall trend is positive, although the second quarter was down. Trial successes with Verzenio, Trulicity, Jardiance and mirikizumab offer additional growth potential.

Covid19_Business_Impact — Lilly took the expected revenue hit during the second quarter but expects normalization during the second half

Lilly Points To Six-Month Growth Instead Of Pandemic Impacted Q2

More from Earnings

More from Business